Severe falciparum malaria with high parasitaemia Infections and Infestations Malaria
Conditions
Interventions
Current information as of 29/07/2010
Patient admitted with severe falciparum malaria and peripheral blood parasitaemia more than or equal to 2% will be randomised to either adjunctive treatment with a single dose of 150 mg oral levamisol
Sponsors
University of Oxford (United Kingdom)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current information as of 29/07/2010: 1. The patient or attending relative, able and willing to give informed consent. The proposed consent form and information sheets are attached and will be translated into the local language. 2. Severe falciparum malaria 3. Peripheral blood parasitaemia more than or equal to 2% 4. Patients aged 16 to 65 years old, both genders 5. No contraindications to levamisole, or artesunate therapy, such as documented allergies to either of the drugs Initial information at time of registration: 1. The patient or attending relative, able and willing to give informed consent. The proposed consent form and information sheets are attached and will be translated into the local language. 2. Severe falciparum malaria 3. Peripheral blood parasitaemia more than or equal to 5% 4. Patients aged 16 to 65 years old, both genders 5. No contraindications to levamisole, or artesunate therapy, such as documented allergies to either of the drugs
Exclusion criteria
Exclusion criteria: Current information as of 29/07/2010: 1. Patient or relatives unable or unwilling to give informed consent 2. More than one dose of previous antimalarial treatment within one week of admission 3. Pregnancy or breastfeeding Initial information at time of registration: 1. Patient or relatives unable or unwilling to give informed consent 2. Previous antimalarial treatment within one week of admission 3. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sequential assessment of peripheral blood parasitaemia and parasite stages. If sequestration is indeed reduced by levamisole, an initial increase in peripheral parasitaemia, and an increase in the number of late stages in the peripheral blood smear can be expected. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Microvascular flow measured using orthogonal polarisation spectral imaging 2. Lactate clearance time | — |
Countries
Bangladesh
Outcome results
None listed